首页> 中文期刊> 《中国药理学报:英文版》 >Differential effects of short-and long-term zolpidem treatment on recombinant α1β2γ2s subtype of GABAA receptors in vitro

Differential effects of short-and long-term zolpidem treatment on recombinant α1β2γ2s subtype of GABAA receptors in vitro

         

摘要

Aim: Zolpidem is a non-benzodiazepine agonist at benzodiazepine binding site in GABAA receptors,which is increasingly prescribed.Recent studies suggest that prolonged zolpidem treatment induces tolerance.The aim of this study was to explore the adaptive changes in GABAA receptors following short and long-term exposure to zolpidem in vitro.Methods: Human embryonic kidney (HEK) 293 cells stably expressing recombinant α1β2γ2s GABAA receptors were exposed to zolpidem (1 and 10 μmol/L) for short-term (2 h daily for 1,2,or 3 consecutive days) or long-term (continuously for 48 h).Radioligand binding studies were used to determine the parameters of [3H]flunitrazepam binding sites.Results: A single (2 h) or repeated (2 h daily for 2 or 3 d) short-term exposure to zolpidem affected neither the maximum number of [3H]flunitrazepam binding sites nor the affinity.In both control and short-term zolpidem treated groups,addition of GABA (1 nmol/L-1 mmol/L) enhanced [3H]flunitrazepam binding in a concentration-dependent manner.The maximum enhancement of [3H]flunitrazepam binding in short-term zolpidem treated group was not significantly different from that in the control group.In contrast,long-term exposure to zolpidem resulted in significantly increase in the maximum number of [3H]flunitrazepam binding sites without changing the affinity.Furthermore,long-term exposure to zolpidem significantly decreased the ability of GABA to stimulate [3H]flunitrazepam binding.Conclusion: The results suggest that continuous,but not intermittent and short-term,zolpidem-exposure is able to induce adaptive changes in GABAA receptors that could be related to the development of tolerance and dependence.

著录项

  • 来源
    《中国药理学报:英文版》 |2012年第12期|1469-1476|共8页
  • 作者单位

    Ruder Bo(s)kovi(c)Institute, Division of Molecular Medicine, Laboratory of Molecular Neuropharmacology, POB 180, Zagreb, Croatia;

    Ruder Bo(s)kovi(c)Institute, Division of Molecular Medicine, Laboratory of Molecular Neuropharmacology, POB 180, Zagreb, Croatia;

    Ruder Bo(s)kovi(c)Institute, Division of Molecular Medicine, Laboratory of Molecular Neuropharmacology, POB 180, Zagreb, Croatia;

    Ruder Bo(s)kovi(c)Institute, Division of Molecular Medicine, Laboratory of Molecular Neuropharmacology, POB 180, Zagreb, Croatia;

    Ruder Bo(s)kovi(c)Institute, Division of Molecular Medicine, Laboratory of Molecular Neuropharmacology, POB 180, Zagreb, Croatia;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号